Trial Profile
Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms LORNET
- Sponsors Roche
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 16 Mar 2012 Actual number of patients changed from 195 to 201 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.